APLT / Applied Therapeutics, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Up to $75,000,000 Common Stock Applied Therapeutics, Inc.

Filed Pursuant to Rule 424(b)(5) Registration No. 333-271887 PROSPECTUS SUPPLEMENT (To Prospectus dated May 19, 2023) Up to $75,000,000 Common Stock Applied Therapeutics, Inc. We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor, dated August 29, 2025, relating to the sale of shares of our common stock, par value $0.0001 p

with a copy to:

Exhibit 10.1 Applied Therapeutics, Inc. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement August 29, 2025 Cantor Fitzgerald & Co. 110 E 59th Street New York, NY 10022 Ladies and Gentlemen: Applied Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follow

FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

FORM 8-K Item 8.01 Other Events.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

Applied Therapeutics Reports Second Quarter 2025 Financial Results - CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline d

Applied Therapeutics Reports Second Quarter 2025 Financial Results - CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD - Presented full 12-month clinical results and new topline data from INSPIRE Phase 2/3 trial of govorestat for the treatment of CMT-SORD at PNS 2025 Annual Meeting highlighting slowed progression of disease observed via MRI at 24 months - Launched new sponsored Sorbitol Assay to support identification of patients suspected of having CMT-SORD - Entered into out-licensing agreement with Biossil, Inc.

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 2. LICENSE AGREEMENT 3. FAIR VALUE MEASUREMENTS 4. PREPAID EXPENSES AND OTHER CURRENT ASSETS 5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES 6. STOCK‑BASED COMPENSATION 7. STOCKHOLDERS’

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 8.01 Other Events.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio

APPLIED THERAPEUTICS INC.

APPLIED THERAPEUTICS INC. Evan Bailey, MD June 13, 2025 Dear Evan: This Amended and Restated Offer Letter (the “Letter Agreement”) confirms the terms and conditions of your employment at Applied Therapeutics Inc. (the “Company”) effective June 15, 2025 (the “Effective Date”). This Letter Agreement amends, restates, and supersedes the offer letter between you and the Company signed on March 15, 202

This letter agreement (this “Agreement”) confirms our agreement regarding the terms of your separation from employment with Applied Therapeutics, Inc. (the “Company”). The Company and you are hereinafter referred to together as the “Parties” and each

Applied Therapeutics Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 212.220.9319 www.appliedtherapeutics.com CONFIDENTIAL June 13, 2025 Riccardo Perfetti Dear Riccardo: This letter agreement (this “Agreement”) confirms our agreement regarding the terms of your separation from employment with Applied Therapeutics, Inc. (the “Company”). The Company and you are hereinafter referred to together

Applied Therapeutics Announces Key Leadership Appointments - Evan Bailey, MD, promoted to Chief Medical Officer, succeeding Riccardo Perfetti, MD, PhD - Dottie Caplan promoted to Executive Vice President, Patient Advocacy and Government Affairs

Applied Therapeutics Announces Key Leadership Appointments - Evan Bailey, MD, promoted to Chief Medical Officer, succeeding Riccardo Perfetti, MD, PhD - Dottie Caplan promoted to Executive Vice President, Patient Advocacy and Government Affairs NEW YORK, June 17, 2025 - Applied Therapeutics, Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 09, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio

Employment Agreement, by and between the Registrant and Todd Baumgartner, dated March 7, 2025.

Exhibit 10.1 APPLIED THERAPEUTICS INC. Todd Baumgartner March 7, 2025 Dear Todd: We are pleased to offer you full time employment with Applied Therapeutics Inc. (the “Company”) under the terms set forth in this offer letter (the “Offer Letter”), effective as of your start date with the Company (such actual date of your commencement of employment shall be referred to herein as the “Start Date”). 1.

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 2. LICENSE AGREEMENT 3. FAIR VALUE MEASUREMENTS 4. PREPAID EXPENSES AND OTHER CURRENT ASSETS 5. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES 6. STOCK‑BASED COMPENSATION 7. STOCKHOLDERS’

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Applied Therapeutics Reports First Quarter 2025 Financial Results - Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Periph

Applied Therapeutics Reports First Quarter 2025 Financial Results - Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting - Review of govorestat development programs for Classic Galactosemia and CMT-SORD Deficiency ongoing NEW YORK, May 13, 2025 – Applied Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commission

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

DEFA14A U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Stock Option Grant Notice and Option Agreement by and between the Registrant and John Johnson, dated December 19, 2024.

Exhibit 99.2 APPLIED THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE Applied Therapeutics, Inc. (the “Company”) hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. Although the Option is not granted pursuant to the Company’s 2019 Equity Incentive Plan (the “Plan”), for purposes of giving it meaning and interpreting its terms, the Opt

Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement by and between the Registrant and John Johnson, dated December 19, 2024.

Exhibit 99.1 APPLIED THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE Applied Therapeutics, Inc. (the “Company”) hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). Although the Award is not made pursuant to the Company’s 2019 Equity Incentive Plan (the “Plan”), for purposes

As filed with the Securities and Exchange Commission on April 24, 2025

As filed with the Securities and Exchange Commission on April 24, 2025 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Applied Therapeutics, Inc.

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D

Insider Trading Policy.

Exhibit 19.1 Applied Therapeutics, Inc. Insider Trading Policy I. Introduction During the course of your relationship with Applied Therapeutics, Inc. (the “Company”), you may receive material information that is not yet public (“material nonpublic information”) about the Company or about other publicly traded companies with which the Company has business relationships. Material nonpublic informati

Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results - Appointed John H. Johnson as Executive Chairman; Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer; and Reena Thomas Colacot as Vice President and Head of Qualit

Applied Therapeutics Reports Fourth Quarter and Year-end 2024 Financial Results - Appointed John H.

In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-388

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Applied Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

NT 10-K 1 aplt-fy24nt10-k3.28.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-38898 CUSIP NUMBER 03828A101 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 2

JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 2 p25-0496exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of fi

JOINT FILING AGREEMENT

EX-99.1 2 ex-99-02142025110246.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Applied Therapeutics, Inc. and further agree that th

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2025 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 APPLIED THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 001-38898 (Commission File

Offer Letter, between John H. Johnson and Applied Therapeutics, Inc., dated as of December 19, 2024

Exhibit 10.1 APPLIED THERAPEUTICS INC. John H. Johnson December 19, 2024 Dear John: We are pleased to offer you full time employment with Applied Therapeutics Inc. (the “Company”) under the terms set forth in this offer letter (the “Offer Letter”), effective as of your start date with the Company (such actual date of your commencement of employment shall be referred to herein as the “Start Date”).

Separation Agreement, between Shoshana Shendelman and Applied Therapeutics, Inc., dated as of December 19, 2024

Exhibit 10.3 Applied Therapeutics Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 212.220.9319 www.appliedtherapeutics.com CONFIDENTIAL December 19, 2024 Shoshana Shendelman c/o Jonathan S. Sack, Esq. Sack & Sack, Attorneys at Law 70 East 55th Street, 10th Floor New York, NY 10022 Dear Shoshana: This letter agreement (this “Agreement”) confirms our agreement regarding the terms of your separa

Amendment to Offer Letter, between Les Funtleyder and Applied Therapeutics, Inc, dated as of December 19, 2024

Exhibit 10.2 APPLIED THERAPEUTICS INC. LETTER AMENDMENT TO OFFER LETTER December 19, 2024 Dear Les: This letter amendment (this “Letter Amendment”) modifies certain provisions set forth in that certain Offer Letter by and between Applied Therapeutics Inc. (the “Company”) and you, dated as of November 17, 2023 (the “Offer Letter”) in connection with your appointment as interim Chief Executive Offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 APPLIED THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 APPLIED THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi

APLT / Applied Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d911992dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03828A 101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statem

APLT / Applied Therapeutics, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm2428137d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock $0.0001 par value per share (Title of Class of Securities) 03828A101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this State

APLT / Applied Therapeutics, Inc. / Vestal Point Capital, LP - APPLIED THERAPEUTICS, INC. Passive Investment

SC 13G/A 1 p24-3221sc13ga.htm APPLIED THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 03828A101 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this sta

APLT / Applied Therapeutics, Inc. / Alyeska Investment Group, L.P. Passive Investment

SC 13G/A 1 alyeska-aplt093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the a

APLT / Applied Therapeutics, Inc. / ALEXANDRIA REAL ESTATE EQUITIES, INC. - SC 13G/A Passive Investment

SC 13G/A 1 tm2428198d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 6) Under the Securities Exchange Act of 1934 APPLIED Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 03828A101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Stateme

Applied Therapeutics Reports Third Quarter 2024 Financial Results - NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in

Exhibit 99.1 Applied Therapeutics Reports Third Quarter 2024 Financial Results - NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in Q1 2025 - NDA submission for govorestat for the treatment of SORD Deficiency under Accelerated Approval expected in early Q1 2025 NEW YO

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

APLT / Applied Therapeutics, Inc. / Shendelman Shoshana - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment. No. 9) Under the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon

Applied Therapeutics Reports Second Quarter 2024 Financial Results -     NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expect

Exhibit 99.1 Applied Therapeutics Reports Second Quarter 2024 Financial Results -     NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action date of November 28, 2024, and EMA decision expected in early Q1 2025         -     FDA Genetic Metabolic Diseases Advisory Committee (GeMDAC) Meeting to discuss NDA for govorestat for th

2019 Equity Incentive Plan, as amended.

Exhibit 10.5 APPLIED THERAPEUTICS, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 24, 2019 APPROVED BY THE STOCKHOLDERS: APRIL 26, 2019 IPO DATE: MAY 13, 2019 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Applied Therapeutics, Inc. 2016 Equity Incentive Plan, as amended from time to time (the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 APPLIED THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi

Amended and Restated Certificate of Incorporation of the Registrant, as amended.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED THERAPEUTICS, INC. Applied Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware, hereby certifies that: 1: The original name of this corporation was Applied Therapeutics, Inc. and the date of filing the original Certificate of Incorporation of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant.

Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Applied Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware (the “Corporation”), hereby certifies that: FIRST:

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commission

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commission

2019 Equity Incentive Plan, as amended.

Exhibit 10.5 APPLIED THERAPEUTICS, INC. 2019 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APRIL 24, 2019 APPROVED BY THE STOCKHOLDERS: APRIL 26, 2019 IPO DATE: MAY 13, 2019 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the Applied Therapeutics, Inc. 2016 Equity Incentive Plan, as amended from time to time (the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Applied Therapeutics Reports First Quarter 2024 Financial Results - Govorestat NDA for Classic Galactosemia under Priority Review, PDUFA target action date of November 28, 2024 - Govorestat MAA under review by EMA; Day 120 3-month clock-stop extensio

Exhibit 99.1 Applied Therapeutics Reports First Quarter 2024 Financial Results - Govorestat NDA for Classic Galactosemia under Priority Review, PDUFA target action date of November 28, 2024 - Govorestat MAA under review by EMA; Day 120 3-month clock-stop extension granted; decision expected in early Q1 2025 - Company discussing potential NDA submission under Accelerated Approval for govorestat for

Applied Therapeutics, Inc. Up to 14,285,714 Shares of Common Stock For Resale Offered by the Selling Stockholders

TABLE OF CONTENTS   Filed pursuant to Rule 424(b)(3)  Registration No. 333-278182 Prospectus Applied Therapeutics, Inc. Up to 14,285,714 Shares of Common Stock For Resale Offered by the Selling Stockholders This prospectus relates to the disposition, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders” on page 7 of up to 14,285,714 s

Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017

Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 April 23, 2024 VIA EDGAR AND EMAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Tim Buchmiller Re: Applied Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-278182) Request for Acceleration of Effective Date Ladies and Gentlemen: We r

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by

Employment letter, by and between Applied Therapeutics, Inc. and Dale Hooks, dated April 9, 2024

Exhibit 10.1 EXECUTION VERSION APPLIED THERAPEUTICS INC. Dale Hooks April 9, 2024 Dear Dale: We are pleased to offer you full time employment with Applied Therapeutics Inc. (the “Company”) under the terms set forth in this offer letter (the “Offer Letter”), effective as of your start date with the Company (such actual date of your commencement of employment shall be referred to herein as the “Star

Separation agreement and general release, by and between Applied Therapeutics, Inc. and Adam Hansard

Exhibit 10.2 Applied Therapeutics Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 212.220.9319 www.appliedtherapeutics.com CONFIDENTIAL April 5, 2024 Adam Hansard Dear Adam: This letter agreement (this “Agreement”) confirms our agreement regarding the terms of your separation of employment with Applied Therapeutics, Inc. (the “Company”). The Company and you are hereinafter referred to togethe

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☒ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 APPLIED THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi

As filed with the Securities and Exchange Commission on March 22, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 22, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) APPLIED THERAPEUTICS, INC.

Various statements in this presentation concerning the Company’s future expectations, plans and prospects constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “es

Exhibit 99.2 Applied Therapeutics SORD 12 Month Interim Data Analysis March 2024 Various statements in this presentation concerning the Company’s future expectations, plans and prospects constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” t

Various statements in this presentation concerning the Company’s future expectations, plans and prospects constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “es

Exhibit 99.1 Applied Therapeutics March 2024 Various statements in this presentation concerning the Company’s future expectations, plans and prospects constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other simil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 APPLIED THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 APPLIED THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-388

Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results - NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA under review

Exhibit 99.1 Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results - NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA under review by EMA with decision expected in 4Q 2024 - Announced positive results from 12-month interim analysis of govorestat in ongoing INSPIRE Pha

Applied Therapeutics, Inc. Clawback Policy

Exhibit 97.1 APPLIED THERAPEUTICS, INC. CLAWBACK POLICY The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Applied Therapeutics, Inc. (the “Company”) believes that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date.

APLT / Applied Therapeutics, Inc. / Shendelman Shoshana - SCHEDULE 13D, AMENDMENT NO. 8 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment. No. 8) Under the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi

Applied Therapeutics Announces $100 Million Private Placement Financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash and cash equivalents

Exhibit 99.1 Applied Therapeutics Announces $100 Million Private Placement Financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2026 NEW YORK, February 28, 2024 – Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage

Securities Purchase Agreement, dated February 27, 2024, by and among the Company and the 2024 Purchasers

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of February 27, 2024, by and among Applied Therapeutics, Inc., a Delaware corporation, with headquarters located at 545 Fifth Avenue, Suite 1400, New York, NY 10017 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Bu

Registration Rights Agreement, dated February 27, 2024, by and among the Company and the 2024 Purchasers

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of February 27, 2024, by and among Applied Therapeutics, Inc., a Delaware corporation, with principal office located at 545 Fifth Avenue, Suite 1400, New York, New York 10017 (the "Company") and the undersigned buyers, (each, a "Buyer" and, collectively, the "Buyers"). WHEREAS: A.    Pursuant to t

Form of 2024 Pre-Funded Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of the registrant’s Current Report on Form 8-K filed March 1, 2024).

Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES L

APLT / Applied Therapeutics, Inc. / Propel Bio Management, LLC - SC 13G/A Passive Investment

SC 13G/A 1 applied-therapeuticssc13ga1.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03828A101 (CUSIP Number) 2/9/2024 (Date of Event which Requires Filing of this Statement) Check the appropriate bo

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi

APLT / Applied Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Passive Investment

SC 13G/A 1 ss3005716sc13ga.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stat

APLT / Applied Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment

SC 13G/A 1 armistice-aplt123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the

APLT / Applied Therapeutics, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm246235d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock $0.0001 par value per share (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stateme

APLT / Applied Therapeutics, Inc. / Alyeska Investment Group, L.P. Passive Investment

SC 13G/A 1 alyeska-aplt123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the ap

AGREEMENT

EX-99.1 2 d518545dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2

APLT / Applied Therapeutics, Inc. / ALEXANDRIA REAL ESTATE EQUITIES, INC. - SC 13G/A Passive Investment

SC 13G/A 1 tm245429d19sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 5) Under the Securities Exchange Act of 1934 APPLIED Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statemen

APLT / Applied Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d518545dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03828A 101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stateme

JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 2 p24-0811exhibit99.htm JOINT ACQUISITION STATEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity o

APLT / Applied Therapeutics, Inc. / Vestal Point Capital, LP - APPLIED THERAPEUTICS, INC. Passive Investment

SC 13G 1 p24-0811sc13g.htm APPLIED THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement)

APLT / Applied Therapeutics, Inc. / FRANKLIN RESOURCES INC Passive Investment

appl23a41.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03828A101 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2023 (Date of

APLT SEC Comment Letter Response – Advanz

APLT SEC Comment Letter Response – Advanz Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 APPLIED THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 APPLIED THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 ( December 28,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2023 ( December 28, 2023) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of

Employment letter, by and between Applied Therapeutics, Inc. and Constantine Chinoporos, dated December 28, 2023.

Exhibit 10.1 APPLIED THERAPEUTICS INC. Constantine Chinoporos December 28, 2023 Dear Constantine: We are pleased to offer you full time employment with Applied Therapeutics Inc. (the “Company”) under the terms set forth in this offer letter (the “Offer Letter”), effective as of your start date with the Company (such actual date of your commencement of employment shall be referred to herein as the

December 21, 2023

December 21, 2023 BY EDGAR Division of Corporate Finance Office of Life Sciences U.

APLT / Applied Therapeutics Inc / FRANKLIN RESOURCES INC Passive Investment

appli23a3.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03828A101 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) November 30, 2023 (Date of

APLT / Applied Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment

SC 13G 1 d35458dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03828A 101 (CUSIP Number) December 4, 2023 (Date of Event Which Requires Filing of this Statement) Check

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 ( November 16,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2023 ( November 16, 2023) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of

Employment Agreement, by and between Applied Therapeutics, Inc. and Les Funtleyder, dated November 17, 2023.

Exhibit 10.1 APPLIED THERAPEUTICS INC. Les Funtleyder November 17, 2023 Dear Les: We are pleased to offer you full time employment with Applied Therapeutics Inc. (the “Company”) under the terms set forth in this offer letter (the “Offer Letter”), effective as of your start date with the Company. Your anticipated start date is November 20, or a date to be mutually agreed upon (such actual date of y

APLT / Applied Therapeutics Inc / Shendelman Shoshana - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment. No. 7) Under the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis

Applied Therapeutics Reports Third Quarter 2023 Financial Results Regulatory submissions on track for govorestat (AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023 Two Upcoming Phase 3 Trial Readouts, with ARISE-HF Trial

Exhibit 99.1 Applied Therapeutics Reports Third Quarter 2023 Financial Results Regulatory submissions on track for govorestat (AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023 Two Upcoming Phase 3 Trial Readouts, with ARISE-HF Trial of AT-001 (caficrestat) in Diabetic Cardiomyopathy on track for data readout in 4Q 2023 and INSPIRE Trial of AT-007 trial in Sorbitol Deh

Exchange Agreement, dated as of October 12, 2023, between Applied Therapeutics, Inc. and Venrock Healthcare Capital Partners EG, L.P., Venrock Healthcare Capital Partners III, L.P. and VHCP Co-Investment Holdings III, LLC.

Exhibit 10.1 October 12, 2023 Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, NY 10017 Re: Warrant Exchange Agreement Ladies and Gentlemen: This letter agreement (the “Agreement”) confirms the agreement of Applied Therapeutics, Inc., a Delaware corporation (the “Company”), and the holders of the Common Stock listed on Schedule I attached hereto (the “Stockholders”), pursuant to w

Form of Exchange Agreement (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on October 13, 2023).

Exhibit 4.1 [THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 APPLIED THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 APPLIED THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

Sales Agreement, dated August 11, 2023, by and between the Company and Leerink Partners LLC.

Exhibit 1.1 Applied Therapeutics, Inc. Up to $75,000,000 of Common Stock ($0.0001 par value) Sales Agreement August 11, 2023 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Applied Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), confirms its agreement (this “Agreement”) with Leerink Par

Up to $75,000,000 Common Stock Applied Therapeutics, Inc.

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-271887 PROSPECTUS SUPPLEMENT (To prospectus dated May 19, 2023) Up to $75,000,000 Common Stock Applied Therapeutics, Inc. We have entered into a sales agreement with Leerink Partners LLC, or Leerink Partners, dated August 11, 2023, or the sales agreement, relating to the shares of our common stock, par value $0.0001 per shar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 APPLIED THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

Applied Therapeutics Reports Second Quarter 2023 Financial Results Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA as well as EMA Marketing Authori

Exhibit 99.1 Applied Therapeutics Reports Second Quarter 2023 Financial Results Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA as well as EMA Marketing Authorization Application planned in Fall 2023 Phase 3 INSPIRE Trial of govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Tria

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 APPLIED THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 (June 6, 2023) APPLI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2023 (June 6, 2023) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporati

Applied Therapeutics, Inc. $300,000,000 Common Stock Preferred Stock Depositary Shares Debt Securities Warrants Offered by Applied Therapeutics, Inc. Up to 38,250,000 Shares of Common Stock Issuable upon Exercise of Warrants Up to 31,735,731 Shares o

TABLE OF CONTENTS  Filed pursuant to Rule 424(b)(3)  Registration No. 333-271887 Prospectus Applied Therapeutics, Inc. $300,000,000 Common Stock Preferred Stock Depositary Shares Debt Securities Warrants Offered by Applied Therapeutics, Inc. Up to 38,250,000 Shares of Common Stock Issuable upon Exercise of Warrants Up to 31,735,731 Shares of Common Stock for Resale Offered by the Selling Stockhold

Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017

CORRESP 1 filename1.htm Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 May 17, 2023 VIA EDGAR AND EMAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Tim Buchmiller Re: Applied Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-271887) Request for Acceleration of Effective Date Ladi

Form of Indenture for debt securities between Applied Therapeutics, Inc. and the trustee to be named therein.

Exhibit 4.3 APPLIED THERAPEUTICS, INC. INDENTURE Dated as of , 20 DEBT SECURITIES , as Trustee Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310(a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 § 311 11.01(f), 16.02 § 312 14.02(d), 16.02 (b) 11.10,16.02 (c) 11.10,16.02 § 313(a) 10.01(a), 16

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) APPLIED THERAPEUTICS, INC.

As filed with the Securities and Exchange Commission on May 12, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 12, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 APPLIED THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commission

Amendment No. 1 to Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of the registrant’s Quarterly Report on Form 10-Q filed May 11, 2023).

AMENDMENT NO. 1 TO COMMON STOCK PURCHASE WARRANT NUMBER Applied Therapeutics, Inc. Amendment Date: , 2022 Reference is made to the above captioned Common Stock Purchase Warrant (the “Original Warrant”) that entitles the holder thereof and identified in the signatures pages hereto (the “Holder”), upon the terms and subject to the limitations on exercise and the conditions set forth in therein, at a

Applied Therapeutics Reports First Quarter 2023 Financial Results Demonstrated Long-term Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial Strengthened Balance Sheet with $30 Million Private Placement of Equity Phase 3 INSPIRE Trial of

Exhibit 99.1 Applied Therapeutics Reports First Quarter 2023 Financial Results Demonstrated Long-term Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial Strengthened Balance Sheet with $30 Million Private Placement of Equity Phase 3 INSPIRE Trial of Govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy on Track for Data in 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

APLT / Applied Therapeutics Inc / FRANKLIN RESOURCES INC Passive Investment

appl23a2.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03828A101 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) April 30, 2023 (Date of Even

APLT / Applied Therapeutics Inc / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Therapeutics, Inc. (Name of Issuer) Common Stock $0.0001 par value per share (Title of Class of Securities) 03828A101 (CUSIP Number) April 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

APLT / Applied Therapeutics Inc / Propel Bio Management, LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03828A101 (CUSIP Number) 2/28/2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched

APLT / Applied Therapeutics Inc / Shendelman Shoshana - SCHEDULE 13D/A; AMENDMENT NO. 6 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment. No. 6) Under the Securities Exchange Act of 1934 APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon

Form of 2023 Pre-Funded Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of the registrant’s Current Report on Form 8-K filed April 27, 2023).

Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 APPLIED THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi

Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity

Exhibit 99.3 Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has entered into a

Form of Pre-Funded Common Stock Purchase Warrant

Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES L

Registration Rights Agreement, dated April 23, 2023, by and among the Company and the 2023 Purchasers.

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of April 23, 2023, by and among Applied Therapeutics, Inc., a Delaware corporation, with principal office located at 545 Fifth Avenue, Suite 1400, New York, New York 10017 (the "Company") and the undersigned buyers, (each, a "Buyer" and, collectively, the "Buyers"). WHEREAS: A. Pursuant to the Sec

Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission · Govorestat demonstrated consistent long-term clinical outcomes benefit acros

Exhibit 99.1 Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission · Govorestat demonstrated consistent long-term clinical outcomes benefit across a range of functional measures in the ACTION-Galactosemia Kids trial, confirming prior biomarker data · Govorestat treatment improved a

ACTION-Galactosemia Kids (AT-007-1002) Clinical Trial Update April 24, 2023 Disclaimer The information contained herein is strictly confidential and is being provided to you solely for your information and to assist you in making your own evaluation

Exhibit 99.2 ACTION-Galactosemia Kids (AT-007-1002) Clinical Trial Update April 24, 2023 Disclaimer The information contained herein is strictly confidential and is being provided to you solely for your information and to assist you in making your own evaluation of Applied Therapeutics, Inc. (the “Company”). For the purposes of this disclaimer, the presentation includes all statements made orally

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2023 APPLIED THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi

Securities Purchase Agreement, dated April 23, 2023, by and among the Company and the 2023 Purchasers.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of April 23, 2023, by and among Applied Therapeutics, Inc., a Delaware corporation, with headquarters located at 545 Fifth Avenue, Suite 1400, New York, NY 10017 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, a "Buyer" and collectively, the "Buyer

definitive proxy statement on Schedule 14A, filed with the SEC on April 17, 2023;

TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted b

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 APPLIED THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi

APLT / Applied Therapeutics Inc / Propel Bio Partners L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Applied Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03828A101 (CUSIP Number) 10/27/2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche

Exclusive License Agreement by and between the Registrant and Mercury Pharma Group Limited, dated January 3, 2023.

EX-10.9 4 aplt-20221231xex10d9.htm EX-10.9 Exhibit 10.9 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. EXCLUSIVE LICENSE AND SUPPLY AGREEMENT by and between APPLIED THERAPEUTICS, INC. and M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-388

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Applied Therapeutics, Inc.

Amended and Restated Certificate of Incorporation of the Registrant, as amended.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED THERAPEUTICS, INC. Applied Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware, hereby certifies that: 1:The original name of this corporation was Applied Therapeutics, Inc. and the date of filing the original Certificate of Incorporation of

As filed with the Securities and Exchange Commission on March 23, 2023

As filed with the Securities and Exchange Commission on March 23, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 APPLIED THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi

Amended and Restated Bylaws of the Registrant.

Exhibit 3.3 AMENDED AND RESTATED BYLAWS OF APPLIED THERAPEUTICS, INC. (A DELAWARE CORPORATION) March 16, 2021 Table of Contents Page ARTICLE I OFFICES‌1 Section 1. Registered Office‌1 Section 2. Other Offices‌1 ARTICLE II CORPORATE SEAL‌1 Section 3. Corporate Seal‌1 ARTICLE III STOCKHOLDERS’ MEETINGS‌1 Section 4. Place of Meetings‌1 Section 5. Annual Meetings.‌1 Section 6. Special Meetings.‌5 Sect

Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, Including Positive Sorbitol Reduction Data from the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehyd

EX-99.1 2 tm2310080d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, Including Positive Sorbitol Reduction Data from the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency On Track to Report Additional Phase 3 Data Across Multiple Progra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 APPLIED THERAPE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi

APLT / Applied Therapeutics Inc / Propel Bio Partners L.P. - SC 13G Passive Investment

SC 13G 1 applied-therapeuticssc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03828A101 (CUSIP Number) 10/27/2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to

APLT / Applied Therapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Passive Investment

SC 13G/A 1 ss1758554sc13ga.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. 3)* Under the Securities Exchange Act of 1934 Applied Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Stat

APLT / Applied Therapeutics Inc / Alyeska Investment Group, L.P. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

APLT / Applied Therapeutics Inc / ARMISTICE CAPITAL, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

APLT / Applied Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G (AMENDMENT NO. 1) Passive Investment

SC 13G/A 1 a021323a.htm SCHEDULE 13G (AMENDMENT NO. 1) 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Applied Therapeutics, Inc. (Ti

APLT / Applied Therapeutics Inc / FRANKLIN RESOURCES INC Passive Investment

appl22in1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03828A101 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2022 (Date of E

APLT / Applied Therapeutics Inc / Knoll Capital Management, LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Applied Therapeutics Inc. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number)

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2023 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi

Applied Therapeutics Reports Third Quarter 2022 Financial Results

Exhibit 99.1 Applied Therapeutics Reports Third Quarter 2022 Financial Results NEW YORK, November 9, 2022 - Applied Therapeutics, Inc. (NASDAQ: APLT) (the ?Company?), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended Sep

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis

Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant.

Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF APPLIED THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Applied Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware (the ?Corporation?), hereby certifies that: FIRST:

APLT / Applied Therapeutics Inc / Shendelman Shoshana - SCHEDULE 13D, AMENDMENT NO. 5 Activist Investment

SC 13D/A 1 sc13da.htm SCHEDULE 13D, AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment. No. 5) APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted b

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by

Applied Therapeutics Reports Second Quarter 2022 Financial Results Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress

Exhibit 99.1 Applied Therapeutics Reports Second Quarter 2022 Financial Results Completed public equity offering with gross proceeds of $30 million Granted orphan medicinal product designation by the EMA for AT-007 for treatment of Galactosemia Continued progress in three registrational Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2H 2022, inclu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 ( August 2, 2022) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorp

APLT / Applied Therapeutics Inc / FRANKLIN RESOURCES INC Passive Investment

appl22in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 03828A101 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Applied Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 03828A101 (CUSIP Number) June 30, 2022 (Date of Event

APLT / Applied Therapeutics Inc / ALEXANDRIA REAL ESTATE EQUITIES, INC. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 4) Under the Securities Exchange Act of 1934 APPLIED Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 03828A101 (CUSIP Number) June 27, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the

Underwriting Agreement, dated June 22, 2022, between the Company and SVB Securities LLC.

EX-1.1 2 tm2219459d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 EXECUTION VERSION Applied Therapeutics, Inc. 20,000,000 Shares of Common Stock ($0.0001 par value) and Pre-Funded Warrants to purchase 10,000,000 Shares of Common Stock and Warrants to purchase 30,000,000 Shares of Common Stock Underwriting Agreement New York, New York June 22, 2022 SVB Securities LLC As Representative of the several Underwrite

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022( June 22, 2022) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorpora

Form of 2022 Common Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.2 of the registrant’s Current Report on Form 8-K filed June 27, 2022).

Exhibit 4.2 COMMON STOCK PURCHASE WARRANT Applied Therapeutics, Inc. Warrant number: Warrant Shares: Issue Date: June 27, 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th

Form of Pre-Funded Warrant to Purchase Common Stock

Exhibit 4.1 COMMON STOCK PURCHASE WARRANT Applied Therapeutics, Inc. Warrant number: Warrant Shares: Issue Date: June 27, 2022 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th

20,000,000 Shares Pre-Funded Warrants to Purchase up to 10,000,000 Shares Warrants to Purchase up to 30,000,000 Shares Common Stock

424B5 1 tm2218967-2424b5.htm 424B5 TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-238948 Prospectus Supplement (To Prospectus dated June 15, 2020) 20,000,000 Shares Pre-Funded Warrants to Purchase up to 10,000,000 Shares Warrants to Purchase up to 30,000,000 Shares Common Stock We are offering 20,000,000 shares of our common stock, par value $0.0001 per share, and accomp

Subject to completion, dated June 22, 2022

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 ( June 2, 2022) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporat

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commission

Applied Therapeutics Reports First Quarter 2022 Financial Results Continued progress in three Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2022

Exhibit 99.1 Applied Therapeutics Reports First Quarter 2022 Financial Results Continued progress in three Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2022 NEW YORK, May 12, 2022 - Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

DEF 14A 1 ny20003386x1def14a.htm DEF 14A TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for U

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.    )

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissi

Offer Letter, by and between Steven Ortega and the Registrant, dated February 1, 2021.

? ? Exhibit 10.15 ? ? ? Applied Therapeutics Inc. 545 Fifth Avenue, Suite 1400 ? New York, NY 10017 ? 212.220.9319 ? www.appliedtherapeutics.com ? ? ? CONFIDENTIAL Steve Ortega 9 Bogert Avenue White Plains, NY 10606 ? Dear Steve: ? Applied Therapeutics Inc., a Delaware corporation (the ?Company?), is pleased to offer you full time employment with the Company under the terms set forth in this offer

Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, with Multiple Clinical and Regulatory Milestones Expected in 2022

Exhibit 99.1 Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, with Multiple Clinical and Regulatory Milestones Expected in 2022 NEW YORK, March 10, 2022 - Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against va

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Applied Therapeutics Corporate Presentation February 2022 This presentation is made by Applied Therapeutics, Inc.(the “Company”). Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the

Exhibit 99.1 Applied Therapeutics Corporate Presentation February 2022 This presentation is made by Applied Therapeutics, Inc.(the ?Company?). Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all- incl

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi

JOINT FILING AGREEMENT

CUSIP No. 03828A101 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Common Stock, par value $0.0001 per share, of Applied Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under th

APLT / Applied Therapeutics Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

APLT / Applied Therapeutics Inc / ALEXANDRIA REAL ESTATE EQUITIES, INC. - SC 13G/A Passive Investment

SC 13G/A 1 tm225987d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3) Under the Securities Exchange Act of 1934 APPLIED Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement

APLT / Applied Therapeutics Inc / Shendelman Shoshana - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment. No. 4) APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis

Equity Distribution Agreement, dated January 26, 2022, by and between the Company and Cowen and Company, LLC.

EX-1.1 2 tm224447d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Applied Therapeutics, Inc. Up to $100,000,000 of Common Stock ($0.0001 par value) Equity Distribution Agreement New York, New York January 26, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, New York 10022 Ladies and Gentlemen: Applied Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”),

Up to $100,000,000 of Common Stock Applied Therapeutics, Inc.

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-238948? PROSPECTUS SUPPLEMENT(To prospectus dated June 15, 2020) ? Up to $100,000,000 of Common Stock Applied Therapeutics, Inc. We have entered into an equity distribution agreement with Cowen and Company, LLC, as our sales agent, under which we may offer and sell from time to time our common stock, par value $0.0001 per s

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commis

APLT / Applied Therapeutics Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Applied Therapeutics, Inc. (Title of Class of Securities) Common Stock, Par Value $0.00

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Applied Therapeutics Reports Third Quarter 2021 Financial Results Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol Data from the ACTION-Galactosemia Kids study demonstrates statistically s

Exhibit 99.1 Applied Therapeutics Reports Third Quarter 2021 Financial Results Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol Data from the ACTION-Galactosemia Kids study demonstrates statistically significant reduction in plasma galactitol NEW YORK, Nov. 12, 2021 ? Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharma

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Applied Therapeutics Reports Second Quarter 2021 Financial Results NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing Ended Q2 2021 with a strong balance sheet with $125.6 million in cash and cash equivalen

Exhibit 99.1 Applied Therapeutics Reports Second Quarter 2021 Financial Results NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing Ended Q2 2021 with a strong balance sheet with $125.6 million in cash and cash equivalents and short-term investments NEW YORK, August 12, 2021 - Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical c

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 (June 3, 2021) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporati

Applied Therapeutics Reports First Quarter 2021 Financial Results Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency NDA submission for AT-007 in Galactosemia expected no later than Q3 2021; commercial preparations ongoing Compl

Exhibit 99.1 Applied Therapeutics Reports First Quarter 2021 Financial Results Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency NDA submission for AT-007 in Galactosemia expected no later than Q3 2021; commercial preparations ongoing Completion of enrollment in ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy on track for mid-2021 Ended 1Q21

Quarterly Report - 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commission

- DEFA14A

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted b

definitive proxy statement on Schedule 14A, filed with the SEC on April 21, 2021;

TABLE OF CONTENTS U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Com

UNITED STATES SECURITIES AND EXCHANGE Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment. No. 3)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment. No. 3) APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon

- S-8

As filed with the Securities and Exchange Commission on April 2, 2021 Registration No.

Applied Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA On track to submit NDA for AT-007 in Galactosemia no later than Q

Exhibit 99.1 Applied Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA On track to submit NDA for AT-007 in Galactosemia no later than Q3 2021; Commercial preparations underway ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy on track to co

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):March 18, 2021 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commissio

Amendment to the Amended and Restated Bylaws of the Registrant.

Exhibit 3.3 ? AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF APPLIED THERAPEUTICS, INC. (the ?Corporation?) A new Article XV of the Amended and Restated Bylaws of the Corporation (the ?Bylaws?) is hereby inserted into the Bylaws as follows: ?ARTICLE XV EXCLUSIVE FORUM PROVISIONS ? Section 48. Federal Forum Selection. Unless the Corporation consents in writing to the selection of an alternative fo

Annual Report - 10-K

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 (February 11, 2021) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of I

Underwriting Agreement, dated February 11, 2021, by and among the Company and Goldman Sachs & Co. LLC, Cowen and Company, LLC and UBS Securities LLC, as representatives of the several underwriters named therein.

Exhibit 1.1 EXECUTION VERSION Applied Therapeutics, Inc. 3,000,000 Shares Common Stock ($0.0001 par value) Underwriting Agreement New York, New York February 11, 2021 Goldman Sachs & Co. LLC Cowen and Company, LLC UBS Securities LLC As Representatives of the several Underwriters, c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o Cowen and Company, LLC 599 Lexington Avenue Ne

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) Under the Securities Exchange Act of 1934 APPLIED Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2) Under the Securities Exchange Act of 1934 APPLIED Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.0001 PAR VALUE PER SHARE (Title of Class of Securities) 03828A101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate

JOINT FILING AGREEMENT

CUSIP No. 03828A101 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 14, 2021 (the “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Applied Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

3,000,000 Shares Common Stock

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(5)? ?Registration No. 333-238948? Prospectus Supplement (To Prospectus dated June 15, 2020) 3,000,000 Shares Common Stock ? We are offering 3,000,000 shares of our common stock, par value $0.0001 per share. Our common stock is listed on The Nasdaq Global Market under the trading symbol ?APLT.? On February 9, 2021, the last reported price of our comm

Subject to completion, dated February 10, 2021

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Applied Therapeutics Reports Third Quarter 2020 Financial Results Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics) On track to initiate rare d

Exhibit 99.1 Applied Therapeutics Reports Third Quarter 2020 Financial Results Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics) On track to initiate rare disease franchise expansion programs in SORD Deficiency and PMM2-CDG studies in the first half of 2021 Continued collaboration with FDA to

Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commi

Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2020

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2020 (August 14, 2020) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incor

APLT / Applied Therapeutics, Inc. / Shendelman Shoshana - SCHEDULE 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment. No. 2) APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon

Applied Therapeutics Reports Second Quarter 2020 Financial Results

Exhibit 99.1 Applied Therapeutics Reports Second Quarter 2020 Financial Results NEW YORK, August 11, 2020 - Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2020. “Th

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38898 Applied Therapeutics, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporation) (Commiss

Equity Distribution Agreement, dated June 12, 2020, by and between the registrant and Goldman Sachs & Co. LLC.

Exhibit 1.2 Applied Therapeutics, Inc. Up to $100,000,000 of Common Stock ($0.0001 par value) Equity Distribution Agreement New York, New York June 12, 2020 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 Ladies and Gentlemen: Applied Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), confirms its agreement (this “Agreement”) with

- S-3/A

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 12, 2020 Registration No.

-

Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 June 12, 2020 VIA EDGAR AND EMAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Courtney Lindsay Re: Applied Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-238948) Request for Acceleration of Effective Date Ladies and Gentlemen: We

- S-3

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 4, 2020 Registration No.

Form of Indenture for debt securities between the Applied Therapeutics, Inc. and the trustee to be named therein.

Exhibit 4.5 APPLIED THERAPEUTICS, INC. INDENTURE Dated as of , 20 DEBT SECURITIES , as Trustee Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310(a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 § 311 11.01(f), 16.02 § 312 14.02(d), 16.02 (b) 11.10,16.02 (c) 11.10,16.02 § 313(a) 10.01(a), 16

- S-3 POS AM

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 4, 2020 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 (June 4, 2020) APPLIED THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38898 81-3405262 (State or Other Jurisdiction of Incorporati

APLT / Applied Therapeutics, Inc. / Shendelman Shoshana - SCHDULE 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment. No. 1) APPLIED THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 03828A 101 (CUSIP Number) Shoshana Shendelman Applied Therapeutics, Inc. 545 Fifth Avenue, Suite 1400 New York, New York 10017 Telephon

Form of Trading Plan.

Exhibit 99.4 Sales Plan Sales Plan, dated as of the date set forth on the signature page (the “Sales Plan”), between Shoshana Shendelman (“Seller”) and Goldman Sachs & Co. LLC (“Broker”). WHEREAS, Seller desires to establish the Sales Plan to sell shares of common stock, par value $0.0001 per share (the “Stock”), of Applied Therapeutics, Inc. (the “Issuer”) in accordance with the requirements of R